Delivery Order 36F79719D0153-36C26223F0022
Award Date
10/17/22
Potential Completion Date
10/16/23
Potential Value
$267K
Federal Agency
Veterans Integrated Service Network 22
Awardee
Genzyme Corporation
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Pittsburgh, PA 15275, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a firm fixed price delivery order contract awarded by the Department of Veterans Affairs (VA) to Genzyme Corporation, doing business as Sanofi Genzyme, a global healthcare and pharmaceutical company. The contract is for the delivery of the specialty pharmaceutical Cerdelga (eliglustat) to support treatment programs for veterans. The contract was awarded under Genzyme's existing $659 million multiple award Federal Supply Schedule (FSS-61-IB) for Pharmaceuticals and Drugs with the VA, as...
This firm fixed-price delivery order was awarded by the Department of Veterans Affairs' (VA) Veterans Health Administration (VHA) to Genzyme Corporation, doing business as Sanofi Genzyme, for the pharmaceutical product Eliglustat (Cerdelga 84mg) under the Pharmaceuticals and Drugs GSA Schedule (FSS-61-IB) contract. The order has a ceiling value of $246,001.38 and a performance period ending on October 26, 2023. Genzyme serves as the prime contractor, with no set-aside designation applied. This...
The Department of Veterans Affairs Veterans Health Administration awarded a firm fixed price delivery order contract to Genzyme Corporation, a division of Sanofi Genzyme, to provide the drug CERDELGA. The contract has a potential value of $106,912.80 and a completion date of March 31, 2019. Genzyme is the prime contractor on this award, which was placed against the company's Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) contract, a multiple award schedule managed by the VA. The...
This is a federal contract award for the delivery of the pharmaceutical product CERDELGA to the Department of Veterans Affairs (VA) Veterans Health Administration. The contract was awarded to the prime contractor Genzyme Corporation, a division of Sanofi Genzyme, on a firm fixed price basis. The contract has a potential value of $106,943.55 and was issued as a delivery order against Genzyme's existing Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) contract with the VA. The...
The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 22 awarded a $265,045.04 firm fixed price delivery order to Genzyme Corporation, doing business under its Genzyme Therapeutics Division, for eliglustat medication. The period of performance is from October 1, 2020 to September 30, 2021. The delivery order was awarded against Genzyme Corporation's Pharmaceuticals and Drugs Federal Supply Schedule contract (FSS-61-IB), with performance taking...
Genzyme Corporation, operating through its Sanofi Genzyme division and Genzyme Therapeutics business unit, has been awarded a $17,830.87 delivery order against the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) prime vendor contract vehicle. The order is for the drug eliglustat to be delivered to the Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 20 located in Cambridge, Massachusetts by March 17, 2020. The delivery order is a firm fixed...
The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 20 awarded a $212,340.40 firm fixed price delivery order against the Pharmaceuticals and Drugs Federal Supply Schedule contract to Genzyme Corporation for the bulk purchase of 84mg oral capsules of Eliqlustat (Cerdelga). Performance will take place in Cambridge, Massachusetts with no set-aside designation applied. Genzyme Therapeutics Division, doing business as Sanofi Genzyme, will serve as the...
Genzyme Corporation, operating through its Sanofi Genzyme division and Genzyme Therapeutics business unit, has been awarded a $17,830.87 delivery order against the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) by the Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 20. The firm fixed price order is for the provision of eliglustat to the agency's Cambridge, Massachusetts facility, with an anticipated completion date of April 19,...
This is a firm fixed price delivery order awarded by the Department of Veterans Affairs (VA) Veterans Integrated Service Network (VISN) 15 to Genzyme Corporation, doing business as Sanofi Genzyme, under the VA's Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) contract. The order is for the specialty pharmaceutical drug alemtuzumab (Lemtrada) and has a ceiling value of $150,854.30. The contract does not have a set-aside designation. Genzyme Corporation serves as the prime...
This federal contract award is for the delivery of the Lemtrada medication to the U.S. Department of Veterans Affairs (VA) Veterans Health Administration (VHA). The $75,582.75 firm fixed price delivery order was awarded to Genzyme Corporation, doing business as Sanofi Genzyme, under the VA's Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) contract. Genzyme is the prime contractor, with no set-aside designation applied. The contract has an ultimate completion date of May 11, 2018...